Aliases & Classifications for Arteriosclerosis

MalaCards integrated aliases for Arteriosclerosis:

Name: Arteriosclerosis 12 54 6 43 15 17 71
Arteriosclerotic Vascular Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2349
MeSH 43 D001161
NCIt 49 C34398
SNOMED-CT 67 28960008 72092001
ICD10 32 I70
UMLS 71 C0003850

Summaries for Arteriosclerosis

Disease Ontology : 12 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries.

MalaCards based summary : Arteriosclerosis, also known as arteriosclerotic vascular disease, is related to arteriosclerosis obliterans and coronary heart disease 1, and has symptoms including angina pectoris An important gene associated with Arteriosclerosis is HS3ST1 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 1), and among its related pathways/superpathways are Degradation of the extracellular matrix and Folate Metabolism. The drugs Pravastatin and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. This... more...

Related Diseases for Arteriosclerosis

Diseases in the Arteriosclerosis family:

Arteriosclerosis, Severe Juvenile

Diseases related to Arteriosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 496)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 35.2 VCAM1 MIR21 ICAM1 HGF ADIPOQ
2 coronary heart disease 1 33.2 VCAM1 SERPINE1 PON1 HS3ST1 HMGCR EDN1
3 coronary artery anomaly 33.2 VCAM1 SERPINE1 PON1 MIR21 ICAM1 HMGCR
4 atherosclerosis susceptibility 33.0 VCAM1 SERPINE1 PPARG PON1 ICAM1 HMGCR
5 hypercholesterolemia, familial, 1 32.1 HMGCR COG2 APOB APOA1
6 peripheral vascular disease 31.7 VCAM1 SERPINE1 HMGCR COG2 APOB APOA1
7 hypertriglyceridemia, familial 31.7 SERPINE1 APOB APOA1
8 ischemia 31.6 PON1 ICAM1 HMOX1 EDN1
9 cerebrovascular disease 31.6 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
10 diabetes mellitus 31.5 VCAM1 SPP1 SERPINE1 PPARG PON1 ICAM1
11 homocysteinemia 31.5 VCAM1 SERPINE1 PON1 ELN CCL2
12 limb ischemia 31.5 SPP1 SERPINE1 ICAM1 HGF EDN1 CCL2
13 lipid metabolism disorder 31.5 SERPINE1 PPARG PON1 HMGCR COG2 CCL2
14 vascular disease 31.5 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
15 coronary stenosis 31.5 SERPINE1 PON1 ICAM1 APOB APOA1 ADIPOQ
16 pulmonary hypertension 31.3 SPP1 SERPINE1 MIR21 HMOX1 EDN1 CCL2
17 carotid stenosis 31.3 VCAM1 SPP1 ICAM1 ADIPOQ
18 hyperglycemia 31.3 VCAM1 SERPINE1 PPARG APOB ADIPOQ
19 hypothyroidism 31.3 SERPINE1 PON1 COG2 APOB APOA1 ADIPOQ
20 arteries, anomalies of 31.3 VCAM1 SERPINE1 MIR21 ICAM1 EDN1 COG2
21 aortic aneurysm, familial abdominal, 1 31.2 ELN DAB2IP CCL2
22 chronic kidney disease 31.2 SPP1 SERPINE1 PON1 MGP HMOX1 HGF
23 aging 31.2 SERPINE1 PPARG EDN1
24 familial hypercholesterolemia 31.2 PON1 HMGCR COG2 APOB APOA1 ADIPOQ
25 takayasu arteritis 31.2 VCAM1 ICAM1 EDN1
26 hyperinsulinism 31.1 SERPINE1 PPARG EDN1 APOB ADIPOQ
27 intermediate coronary syndrome 31.1 VCAM1 ICAM1 COG2 APOB APOA1
28 peripheral artery disease 31.1 VCAM1 ICAM1 HMOX1 HGF EDN1 CCL2
29 kidney disease 31.0 VCAM1 SPP1 SERPINE1 PPARG PON1 MGP
30 cerebral aneurysms 31.0 ELN CCL2
31 heart disease 31.0 VCAM1 SERPINE1 PPARG PON1 MIR21 ICAM1
32 carotid artery disease 31.0 PON1 COG2 CCL2 APOB APOA1
33 stroke, ischemic 31.0 SERPINE1 PON1 HMGCR COG2 APOB
34 proteasome-associated autoinflammatory syndrome 1 31.0 VCAM1 PPARG ICAM1 CCL2 ADIPOQ
35 body mass index quantitative trait locus 11 31.0 VCAM1 SERPINE1 PPARG PON1 MIR21 ICAM1
36 uremia 31.0 SPP1 PON1 MGP
37 systemic lupus erythematosus 31.0 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
38 glucose intolerance 31.0 SERPINE1 PPARG CCL2 APOB APOA1 ADIPOQ
39 hypertension, essential 31.0 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
40 non-alcoholic steatohepatitis 31.0 PPARG PON1 ADIPOQ
41 glomerulonephritis 30.9 VCAM1 SPP1 ICAM1 CCL2
42 aortic atherosclerosis 30.9 SPP1 PON1 ADIPOQ
43 connective tissue disease 30.9 SPP1 MIR21 ELN EDN1 CCL2
44 hyperlipidemia, familial combined, 3 30.9 PON1 COG2 APOB APOA1 ADIPOQ
45 non-alcoholic fatty liver disease 30.9 SERPINE1 PPARG MIR21 HMGCR APOB APOA1
46 retinal vascular disease 30.8 VCAM1 MIR21 ICAM1 EDN1 CCL2
47 sleep apnea 30.8 VCAM1 ICAM1 EDN1 CCL2 APOB ADIPOQ
48 osteoporosis 30.8 SPP1 SERPINE1 PPARG MIR21 MGP ICAM1
49 acute myocardial infarction 30.8 SERPINE1 MIR21 HMGCR EDN1 APOB APOA1
50 coronary artery aneurysm 30.7 VCAM1 CCL2 ADIPOQ

Graphical network of the top 20 diseases related to Arteriosclerosis:



Diseases related to Arteriosclerosis

Symptoms & Phenotypes for Arteriosclerosis

UMLS symptoms related to Arteriosclerosis:


angina pectoris

MGI Mouse Phenotypes related to Arteriosclerosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 ADIPOQ APOA1 APOB EDN1 HGF HMOX1
2 homeostasis/metabolism MP:0005376 10.22 ADIPOQ APOA1 APOB COG2 DAB2IP EDN1
3 growth/size/body region MP:0005378 10.21 ADIPOQ APOB COG2 EDN1 HGF HMGCR
4 cellular MP:0005384 10.18 ADIPOQ APOA1 APOB DAB2IP HGF HMOX1
5 mortality/aging MP:0010768 10 ADIPOQ APOB COG2 EDN1 HGF HMGCR
6 liver/biliary system MP:0005370 9.91 ADIPOQ APOA1 APOB HGF HMGCR HMOX1
7 muscle MP:0005369 9.56 ADIPOQ APOB EDN1 HMOX1 ICAM1 MGP
8 renal/urinary system MP:0005367 9.17 ADIPOQ EDN1 HMOX1 MGP PPARG SERPINE1

Drugs & Therapeutics for Arteriosclerosis

Drugs for Arteriosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Polyestradiol phosphate Approved Phase 4 28014-46-2
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
10
Dipyridamole Approved Phase 4 58-32-2 3108
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Ezetimibe Approved Phase 4 163222-33-1 150311
13
Metformin Approved Phase 4 657-24-9 4091 14219
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Insulin aspart Approved Phase 4 116094-23-6 16132418
16
Insulin detemir Approved Phase 4 169148-63-4 5311023
17
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
18
Simvastatin Approved Phase 4 79902-63-9 54454
19
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
20
Fenofibrate Approved Phase 4 49562-28-9 3339
21
Atenolol Approved Phase 4 29122-68-7 2249
22
Propranolol Approved, Investigational Phase 4 525-66-6 4946
23
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Calcium acetate Approved, Investigational Phase 4 62-54-4
26
Sevelamer Approved Phase 4 52757-95-6
27
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
28
Liraglutide Approved Phase 4 204656-20-2 44147092
29
Methyltestosterone Approved Phase 4 58-18-4 6010
30
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
31
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
32
Testosterone enanthate Approved Phase 4 315-37-7 9416
33
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
34
Amlodipine Approved Phase 4 88150-42-9 2162
35
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
36
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
37
Probucol Approved, Investigational Phase 4 23288-49-5 4912
38
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
39
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
40
tannic acid Approved Phase 4 1401-55-4
41
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
42
Chlorthalidone Approved Phase 4 77-36-1 2732
43
Allopurinol Approved Phase 4 315-30-0 2094
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
47
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
48
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
49
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
50
Mycophenolic acid Approved Phase 4 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 428)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
3 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
4 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
5 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
6 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
7 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
8 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
9 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
10 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
11 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
12 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
13 Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial Completed NCT00292721 Phase 4 Celecoxib
14 A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Completed NCT00380939 Phase 4 Atorvastatin;Pravastatin
15 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
16 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
17 A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis Completed NCT00163202 Phase 4 Atorvastatin
18 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
19 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
20 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
21 A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus Completed NCT00368953 Phase 4
22 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
23 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
24 Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts. Completed NCT00611910 Phase 4
25 A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population. Completed NCT00319449 Phase 4 Ezetimibe;Placebo;Atorvastatin 10 mg
26 The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial Completed NCT00657943 Phase 4 metformin;insulin detemir;insulin aspart + insulin aspart protamin;Insulin aspart
27 A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease Completed NCT01706510 Phase 4 Ticagrelor;Clopidogrel
28 Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Completed NCT02510547 Phase 4
29 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
30 Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism Completed NCT00274144 Phase 4 telmisartan 40 mg;placebo 40 mg
31 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
32 Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI Completed NCT00390585 Phase 4 Iodixanol 320;Iomeprol 350
33 Pharmacogenomics of Antiplatelet Response - II Completed NCT01894555 Phase 4 Aspirin
34 Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA) Completed NCT01325935 Phase 4 Clopidogrel
35 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
36 Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression Completed NCT00204321 Phase 4 sirolimus (drug), mmf (drug)
37 Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure Completed NCT00347087 Phase 4 Irbesartan
38 Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids Completed NCT00296153 Phase 4 Omega-3-acid ethyl esters 90
39 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
40 Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population Completed NCT02153879 Phase 4 Fenofibrate;Niacin plus laropiprant
41 A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease Completed NCT00471341 Phase 4 Celecoxib;placebo
42 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
43 Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE) Completed NCT00351676 Phase 4 Optimizing therapeutic treatments
44 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
45 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
46 The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound. Completed NCT01385631 Phase 4 Ezetimibe;Placebo
47 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
48 Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients Completed NCT01612468 Phase 4 Liraglutide;Placebo
49 Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study Completed NCT01374698 Phase 4 Aspirin
50 Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis Completed NCT03485495 Phase 4 Divaza;Placebo

Search NIH Clinical Center for Arteriosclerosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: arteriosclerosis

Genetic Tests for Arteriosclerosis

Anatomical Context for Arteriosclerosis

MalaCards organs/tissues related to Arteriosclerosis:

40
Heart, Endothelial, Kidney, Smooth Muscle, Brain, Testes, Bone

Publications for Arteriosclerosis

Articles related to Arteriosclerosis:

(show top 50) (show all 11591)
# Title Authors PMID Year
1
Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. 54 61
20097344 2010
2
Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. 54 61
20150911 2010
3
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 54 61
20078196 2010
4
Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. 54 61
19066833 2009
5
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. 54 61
19132220 2008
6
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. 61 54
18464944 2008
7
Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. 61 54
18670142 2008
8
Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. 61 54
18332637 2008
9
[Endothelin-1 production and its involvement in cardiovascular diseases]. 54 61
17827914 2007
10
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]. 54 61
17489075 2007
11
General anesthesia and methylenetetrahydrofolate reductase deficiency. 54 61
18008117 2007
12
[Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells]. 54 61
17274908 2006
13
Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. 61 54
16844909 2006
14
Endothelial-mediated regulation of cerebral microcirculation. 61 54
17244945 2006
15
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 54 61
16616959 2006
16
TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. 61 54
16796604 2006
17
Protective genes in the vessel wall: Modulators of graft survival and function. 61 54
16829794 2006
18
Signaling and functions of angiopoietin-1 in vascular protection. 61 54
16645151 2006
19
Recent advances in the relationship between obesity, inflammation, and insulin resistance. 54 61
16613757 2006
20
[Effects of active components extracted from Qixue Bingzhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor genes]. 54 61
16409966 2006
21
Adrenomedullin: a protective factor for blood vessels. 61 54
16141406 2005
22
Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. 54 61
15882555 2005
23
Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. 54 61
15744522 2005
24
Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. 61 54
15578196 2005
25
Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. 61 54
15550473 2005
26
[Endothelin-1 and arteriosclerosis]. 61 54
15506470 2004
27
Eukaryotic expression vector of heme oxygenase-1 and its expression in endothelial cell. 61 54
15313669 2004
28
CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. 54 61
15257175 2004
29
Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. 54 61
15181084 2004
30
Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. 54 61
15072997 2004
31
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. 61 54
15225502 2004
32
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 61 54
14963043 2004
33
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. 61 54
14691581 2004
34
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. 61 54
12942166 2003
35
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 61 54
14581407 2003
36
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. 61 54
14583180 2003
37
[Neurological aspects in antiphospholipid syndrome]. 61 54
15152454 2003
38
[Regulatory effect of yishou tiaozhi tablet on lipids in patients with primary hyperlipidemia]. 61 54
12764909 2003
39
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 54 61
12628953 2003
40
The concentration of lipids, lipoproteins and apolipoproteins in cord blood serum of newborns in the course of intrauterine period. 54 61
15323161 2003
41
Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. 54 61
12791519 2003
42
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. 54 61
12411463 2002
43
Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. 54 61
12231371 2002
44
Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. 61 54
12452315 2002
45
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. 61 54
12616975 2002
46
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. 54 61
12560586 2002
47
A survey of the dietary nutritional composition of centenarians. 61 54
11677774 2001
48
[Effect of lower androgen levels on arteriosclerosis]. 54 61
11769606 2001
49
Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. 54 61
11342471 2001
50
Metabolism of hepatocyte growth factor in the heart in patients with coronary artery disease: implication for coronary arteriosclerosis. 54 61
11669408 2001

Variations for Arteriosclerosis

ClinVar genetic disease variations for Arteriosclerosis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HS3ST1 NM_005114.3(HS3ST1):c.-108-6848A>GSNV risk factor 441163 rs16881446 4:11408585-11408585 4:11406961-11406961

Expression for Arteriosclerosis

Search GEO for disease gene expression data for Arteriosclerosis.

Pathways for Arteriosclerosis

Pathways related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 VCAM1 SPP1 SERPINE1 ICAM1 ELN
2
Show member pathways
12.16 SERPINE1 ICAM1 CCL2 APOB APOA1
3 11.86 VCAM1 ICAM1 HMOX1 EDN1 CCL2